؉ T cells result in T cell accumulation in the liver, associated with T cell apoptosis and liver injury. However, the role of Ag and APC in such accumulation is not clear. Bone marrow chimeras were constructed to allow Ag presentation in all tissues or alternatively to restrict presentation to either bone marrow-derived or non-bone marrowderived cells. OVA-specific CD8 ؉ T cells were introduced by adoptive transfer and then activated using peptide, which resulted in clonal expansion followed by deletion. Ag presentation by liver non-bone marrow-derived cells was responsible for most of the accumulation of activated CD8 ؉ T cells. In contrast, Ag presentation by bone marrow-derived cells resulted in less accumulation of T cells in the liver, but a higher frequency of apoptotic cells within the intrahepatic T cell population. In unmodified TCRtransgenic mice, Ag-induced T cell deletion and intrahepatic accumulation of CD8 ؉ T cells result in hepatocyte damage, with the release of aminotransaminases. Our experiments show that such liver injury may occur in the absence of Ag presentation by the hepatocytes themselves, arguing for an indirect mechanism of liver damage.
A ctivated CD8
ϩ T cells undergo massive clonal expansion, redistribution via the blood to nonlymphoid organs, and finally apoptosis. Changes in adhesion molecules allow the mobilization of activated effector cells from lymphoid organs into the blood, with subsequent flow through all vascular beds. Localization to sites of inflammation depends on up-regulation of adhesion molecules on vascular endothelium, which results in lymphocyte rolling, followed by firm adhesion to the endothelium, mediated by integrins such as ICAM-1 (1, 2) . In parallel, the T cell growth factor IL-2 promotes the expression of the proapoptotic factor, Fas ligand (FasL 3 ; CD95L), and the disappearance of the caspase-8 antagonist, Fas-like IL-1-converting enzyme-inhibitory protein (3) . These changes predispose the activated T cells to apoptosis through Fas-FasL interactions. The fate of those activated CD8 ϩ T cells that do not localize to an inflamed target site is controversial. The expression of FasL has been reported in a number of nonlymphoid tissues (4) , and among these the liver is distinctive in expressing a high density of ICAM-1 (5, 6) . It is therefore natural to consider the possibility that the liver has the potential both to trap and to kill activated circulating T cells.
We and others have reported the accumulation and apoptosis of activated CD8 ϩ T cells in the liver during systemic immune responses (7) (8) (9) (10) . ICAM-1 appears to be important in this process. When a mixture of resting and activated T cells were perfused through a mouse liver, the activated CD8 ϩ T were selectively retained (11) , but this retention was compromised in an ICAM-1-deficient liver. Most of the retained CD8 ϩ T cells were in contact with Kupffer cells, a highly mobile population of hepatic macrophages. By 14 h, a proportion of the trapped CD8 ϩ T cells had begun to undergo apoptosis. These findings support the idea that the liver is a trap for activated CD8 ϩ T cells and that such trapping results in their apoptosis.
In many experimental and physiological immune responses, Ag presented on liver cells leads to tolerance, which may be linked to T cell apoptosis (12) (13) (14) . To explain the tolerogenic property of liver Ags, we propose the hypothesis that recognition of Ag on the liver tissue (i.e., on sinusoidal endothelium and/or hepatocytes) promotes T cell trapping and apoptotic death. This hypothesis predicts that the capacity of hepatic non-bone marrow-derived cells to present Ag will control the trapping and apoptosis of CD8 ϩ T cells in the liver and thus regulate CD8 ϩ T cell removal from the circulating pool. To test these predictions, we developed a model in which naive CD8 ϩ T cells from the OT-1 transgenic mouse, expressing a TCR specific for the OVA peptide SIINFEKL, were adoptively transferred into chimeric mice which had received lethal irradiation followed by reconstitution with donor bone marrow. These chimeras were constructed so that Ag presentation could occur on all cells, or alternatively was restricted either to bone marrow-derived cells, or to non-bone marrow-derived cells. Systemic activation of CD8 ϩ T cells resulted in accumulation and apoptosis of activating CD8 ϩ T cells in the liver. The ability of non-bone marrow-derived cells to present Ag was essential for the hepatic accumulation of CD8 ϩ T cells. Chimeras in which these tissues were unable to present Ag accumulated fewer T cells in the liver, and this was associated with impaired deletion of activated CD8 ϩ T cells from the spleen. This supports a role for the liver in systemic CD8 ϩ T cell homeostasis.
Immune mediated liver injury occurs in a wide variety of systemic immune responses (15, 16) . Such injury of hepatocytes may occur by classical, MHC-restricted recognition of specific antigenic peptides on hepatocytes, e.g., during immunopathology associated with the CD8 ϩ T cell response to hepatitis B virus Ags (17) . It has also been proposed that physiological T cell activation can result in hepatic damage simply because of the presence of activated cytotoxic cells T cells in the liver, a mechanism termed collateral damage (18) . In the present series of experiments, chimeric mice in which the hepatocytes were unable to support Ag recognition nevertheless showed evidence of liver damage associated with an activated CD8 ϩ T cell influx. This study thus provides evidence for the collateral damage mechanism.
Materials and Methods

Animals
Nontransgenic C57BL/6J and H2-K bm1 mice (on the C57BL/6J background) and C57BL/6 mice of the CD45.1 allotype were purchased from The Jackson Laboratory (Bar Harbor, ME). A colony of OT-1-transgenic mice was maintained on the C57BL/6J background. All animals were housed in a specific pathogen-free environment, in accordance with institutional guidelines for animal care.
To construct chimeras, 6-to 8-wk-old recipient mice were irradiated with 13 Gy (1300 rad) as a single dose from a cesium irradiator. Mature T cells were removed from donor bone marrow cell suspensions by complement-mediated lysis of T cells, and between 10 and 15 ϫ 10 6 T celldepleted bone marrow cells were injected i.v. within 4 h of irradiation. All chimeras were allowed to reconstitute for 2 mo before further experimentation. Three types of chimeras were made: C57BL/6J3 C57BL/6J; H2-K bm1 3 C57BL/6J; and C57BL/6J3 H2-K bm1 . OT-1 T cells were activated after adoptive transfer by daily i.p. injections of 25 nM SIINFEKL peptide for 3 days starting on day 2, as previously described (9) . Control mice received saline. To control for any liver toxicity of the SIINFEKL peptide, chimeras without OT-1 cells received the same dosage of the peptide.
Adoptive transfer and in vivo activation
Cell isolation, staining, and flow cytometric analysis
At days 3, 5, and 7 after the first peptide or saline injections, mice were anesthetized with methoxyflurane (Schering-Plough Animal Health, Kenilworth, NJ), and exsanguinated by cutting the abdominal aorta and vena cava. Blood was collected from the abdominal cavity using a heparinized 1-ml syringe, and the serum was assayed for the enzymes aspartate aminotransminase (AST) and alanine aminotransaminase (ALT) using a multichannel analyzer.
Intrahepatic lymphocytes were isolated by perfusion of the liver with digestion buffer consisting of Bruff's medium containing 0.02% collagenase IV (Sigma, St. Louis, MO), 0.002% DNase I (Sigma), and 5% FCS. The digestion buffer was infused into the portal vein using a 5-ml syringe and a 21-gauge needle during 1-2 min. Care was taken to minimize injection of air bubbles into the portal vein, and blanching of the whole liver was used as an indicator of adequate perfusion. After perfusion, the liver was dissected out of the abdominal cavity and homogenized by forcing through a fine metal strainer. The homogenized liver was incubated with 10 ml digestion buffer at 37°C for 30 min in a shaking water bath. The enzymatically digested liver cell suspension was centrifuged at 10 ϫ g for 3 min at 4°C to remove hepatocytes and cell clumps. The supernatant was then centrifuged at 120 ϫ g for 10 min to obtain a pellet of cells depleted of hepatocytes. The volume of the pellet was typically 0.3-0.5 ml, and it was suspended with Bruff's medium to a final volume of 1 ml, before being mixed with 4 ml 30% metrizamide in Bruff's medium. This procedure resulted in 5 ml cell suspension in 24% metrizamide, which was layered under 1 ml serum-free Bruff's medium and centrifuged at 1500 ϫ g for 20 min at 4°C in 15-ml conical centrifuge tubes (Falcon, Franklin Lake, NJ). The cells at the interface were collected, washed with PBS, and counted before analysis using a FACS.
As a control to discriminate liver-specific effects on T cell accumulation and apoptosis from generic properties of nonlymphoid organs, kidney T cells were analyzed in parallel. Kidneys were cut into 2-to 3-mm slices, homogenized by forcing through a metal strainer, and then digested with collagenase. Renal lymphocytes were isolated using metrizamide, as described above. The spleen was dissected, homogenized and RBC were lysed using RBC lysing buffer (Sigma). Lymphocytes were washed and counted before staining for FACS analysis. Sections of liver and kidney were cut and fixed in 1% paraformaldehyde in PBS for histological analysis before homogenization.
Cells were adjusted to 2 ϫ 10 7 /ml in staining buffer (saline with 1% bovine albumin). Fifty microliters of the cell suspension were incubated with Ab on ice for 30 min, washed with staining buffer, and fixed with 2% paraformaldehyde. FACS data were acquired using a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA), set to acquire all events. The Abs used for staining were TCR␣␤ (clone H57-597), CD45.1 (clone A20), CD45.2 (clone 104), L-selectin (clone MEL-14), LFA-1 (clone 2D7), V␣2 (clone B20.1), and CD8 (clone 53-6.7). For TUNEL staining of cell suspensions and tissue sections, the In Situ Cell Death Detection Kit-Fluorescein (Boehringer Mannheim, Indianapolis, IN) was used according to the manufacturer's instructions. FACS data were analyzed using CellQuest software (BD Biosciences).
Results
Hepatic accumulation and apoptosis of CD8 ϩ T cells occur even at low precursor frequencies
Peripheral deletion and massive liver accumulation and apoptosis of the responding cells were previously reported using TCR-transgenic mice (7, 9) , leaving open the possibility that these effects might be limited to mice with a very high frequency of responding T cells. To test this and to establish a system to determine the role of hepatic Ag presentation in this phenomenon, we adoptively transferred 5 ϫ 10 6 CD8 ϩ T cells from OT-1 mice on the C57BL/6J background into unmanipulated nontransgenic C57BL/6J mice (19) . The OT-1 mice are transgenic for a TCR that recognizes the 8-mer OVA peptide, SIINFEKL, in association with the MHC molecule H2-K b . In all of these experiments, the adoptively transferred T cells were CD45.1/CD45.2 heterozygous, permitting their identification by FACS.
After adoptive transfer, the OT-1 cells were present at low frequency (1% or less) in the spleen, liver, and kidney. Daily i.p. injections of saline did not alter the total numbers of lymphocytes or the percentage of OT-1 cells during 7 days (Fig. 1) . Daily injections of 250 l 100 M SIINFEKL peptide (i.e., 25 nM peptide) beginning on day 2 after adoptive transfer resulted in no significant change in cell numbers in the spleen or kidney, but an ϳ7-fold increase in the number of intrahepatic lymphocytes. The percentage of OT-1 cells increased in all three organs after peptide administration, but the largest increase was in the liver at 25-fold, compared with the spleen and kidney where the increase was 7-and 10-fold, respectively (Fig. 1) . The number of OT-1 cells in each organ was calculated by multiplying the total number of lymphocytes by the percentage of OT-1 cells. The maximum number of OT-1 cells in the spleen was at day 3 after peptide injection, at 12.4 Ϯ 3.8 ϫ 10 6 , decreasing to 5.2 Ϯ 3.1 ϫ 10 6 on day 5, whereas maximum accumulation in the liver was later, with 6.3 Ϯ 2.4 ϫ 10 6 OT-1 cells at day 5. By comparison the kidney contained relatively few OT-1 cells, 7.4 Ϯ 1.8 ϫ 10
4 . In all, there was a 170-fold increase in the total number of OT-1 cells in the liver, compared with 13-and 24-fold in the spleen and kidney, respectively.
Thus, the behavior of OT-1 T cells was very similar in the spleen and the kidney. Clonal expansion on day 3 was followed by loss of the expanded cells over days 5 and 7. In contrast, a much larger expansion of the OT-1 cell number in the liver occurred with delayed kinetics, at day 5. The data show that, although nonquantitative histological analysis reveal apoptotic CD8
ϩ T cells at many tissue sites including the liver, kidneys, lungs, and intestine (20) , the liver is quite distinctive in both the kinetics and the magnitude of activated CD8
ϩ T cell accumulation.
A key finding in earlier studies was the high frequency of apoptotic CD8 ϩ T cells accumulating in the liver (7) (8) (9) (10) . This was confirmed in the present study, in which the percentage of OT-1 cells which were TUNEL positive in the spleen, liver, and kidney were 8.4 Ϯ 2.7%, 18.3 Ϯ 5.2% and 9.6 Ϯ 4.3%, respectively. In the PBS-injected control chimeras, there were too few OT-1 cells to obtain TUNEL information.
Ag presentation by non-bone marrow-derived cells enhances intraheptic accumulation of activated CD8
ϩ T cells
The OT-1-transgenic TCR recognizes the SIINFEKL peptide in association with H2-K b . The H2 molecule H2-K bm1 differs from H2-K b by three amino acids at positions 152, 155, and 156, and this difference is sufficient to prevent effective presentation of the SIINFEKL peptide (21) .
In the C57BL/6J (H2-K b ) mice, all cells of the liver were able to present the SIINFEKL peptide to OT-1 T cells. To study the effect on liver accumulation of OT-1 T cells in the absence of Ag presentation by non-bone marrow-derived cells, we generated chimeras in which C57BL/6J bone marrow was infused into B6.C-H2 bm1 (H2-K bm1 ) hosts (B63bm1). In these chimeras, Ag presentation to OT-1 cells was possible by bone marrow-derived cells only. C57BL/6J into C57BL/6J (B63 B6) and B6.C-H2
bm1 into C57BL/6 of the CD45.1 allotype (bm13 B6.CD45.1) provided the controls. The negative control of B6.C-H2 bm1 into B6.C-H2 bm1 chimeras are not suitable recipients for OT-1 cells, because they mount an alloimmune response to the H2-K b molecule expressed on the T cells. In control experiments, OT-1 cells transferred into intact B6.C-H2 bm1 hosts simply disappeared, probably due to allorejection. The donors and recipients for B63 B6 and B63bm1 were CD45.2, but the recipients for bm13 B6.CD45.1 chimeras were C57BL/6J mice with the CD45.1 allotype. This allowed analysis of the percentage of donor bone marrow-derived cells (CD45.2), recipient bone marrow-derived cells (CD45.1), and donor OT-1 T cells (CD45.1/CD 45.2 heterozygous) (see Fig. 2) .
Preliminary experiments identified day 5 as a time point when removal of most of the OT-1 cells from the spleen had occurred, and the liver accumulation was maximal. Fig. 2 shows clonal expansion of OT-1 cells in the spleens of all three groups of chimeras at day 5 after peptide injection. OT-1 T cell expansion in B63 B6 and B63bm1 chimeras was expected, due to the presence of H2-K b on bone marrow cells. Expansion in the bm13 B6.CD45.1 was likely due to the persistence of recipient bone marrow-derived cells despite irradiation, and these are identifiable by FACS analysis as CD45.1 positive but CD45.2 negative (Fig. 2) . They constituted 4.3 Ϯ 1.4% of all the bone marrow-derived cells in the spleens of bm13 B6 chimeras injected with PBS. Therefore, the full activation of OT-1 cells in these chimeras should not be taken to imply that activation was independent of bone marrow-derived cells. Fig. 3 show the percentage and total number of OT-1 T cells in the livers of the three groups of chimeras after 5 days of saline or peptide injection. Peptide injection resulted in accumulation of OT-1 cells in the livers of mice in all three groups of chimeras. B63 B6 and bm13 B6.CD45.1 chimeras were able to present SIINFEKL peptide on non-bone marrow-derived cells, and the number of OT-1 cells were similar to those seen in normal C57BL/6 mice. These numbers were 6.4 ϫ 10 6 Ϯ 1.7 ϫ 10 6 in the B63 B6 and 5.9 ϫ 10 6 Ϯ 1.1 ϫ 10 6 in the bm13 B6 chimeras, and these numbers were not significantly different by an unpaired t test ( p ϭ 0.5). In B63bm1 chimeras, hepatocytes and endothelial cells were unable to present Ag, and the numbers of OT-1 cells in the livers of these chimeras was 2.4 ϫ 10 6 Ϯ 0.9 ϫ 10 6 , which is significantly different from both the value in B63 B6 chimeras ( p ϭ 0.002) and the value in bm13 B6 chimeras ( p ϭ 0.001). There were no significant differences among the three groups of There was an increase in the OT-1 population after peptide injection with a peak at day 3 and a rapid decline by day 7 (A and D). A greater increase was evident in the liver, with a peak at a later time point, day 5 (B and E). The kinetics in the kidney were similar to the spleen, but of a lower magnitude (C and F). The total numbers of OT-1 cells (10 6 ) follow the same kinetics as the percentages of OT-1 cells. The very large increase in cell number the liver was due to a 7-fold increase in total liver lymphocyte count. The total numbers of lymphocytes in the spleen and kidney did not change significantly after peptide injection. chimeras in the number of OT-1 cells in the kidney after peptide injection (Fig. 3 , E and F, p Ͼ 0.8 in all cases).
Ag presentation by non-bone marrow-derived cells enhances peripheral deletion of OT-1 cells from the spleen
The greater liver accumulation of OT-1 cells in B63 B6 chimeras relative to B63bm1 was associated with lower percentages and total numbers of OT-1 cells in the spleen of B63 B6 chimeras (Fig. 3, C and D) . Thus, the B63 B6 chimeras contained 3.22 ϫ 10 6 Ϯ 1.78 ϫ 10 6 OT-1 cells, whereas the B63bm1 chimeras contained 10.5 ϫ 10 6 Ϯ 2.0 ϫ 10 6 OT-1 T cells, a difference that was significant based on an unpaired t test ( p ϭ 0.001). This suggests that the removal of activated OT-1 cells from the spleen was compromised because of the reduced accumulation of OT-1 cells in the liver of the B63bm1 chimeras. The B63 B6 and B63bm1 chimeras do not differ only in Ag presentation by hepatocytes and endothelial cells, because nonbone marrow-derived cells of other organs in the B63bm1 chimeras would also be unable to present the SIINFEKL peptide to OT-1 cells. To study the effect of Ag presentation by non-bone marrow-derived cells in another organ, the percentage and total number of OT-1 cells in the kidneys were determined in chimeras of all three groups. There was an ϳ15-to 24-fold increase in the number of OT-1 cells in the kidney in peptide-injected mice compared with PBS-injected controls (from ϳ2 ϫ 10 3 to 40 ϫ 10 3 ). There were, however, no significant differences between different groups of chimeras in the total number of OT-1 cells in the kidneys. The kidneys of B63 B6 chimeras contained 48 ϫ 10 3 Ϯ 18 ϫ 10 3 OT-1 cells, the kidneys of B63bm1 chimeras contained 49 ϫ 10 3 Ϯ 21 ϫ 10 3 OT-1 cells, and the kidneys of bm13 B6 chimeras contained 45 ϫ 10 3 Ϯ 21 ϫ 10 3 OT-1 cells. None of these differences was significant by an unpaired t test ( p Ͼ 0.8 in every case).
Thus, in the absence of an inflammatory stimulus, the presence of Ag on tissue cells did not enhance the localization of activated T cells to the kidney. An experiment conducted in transgenic mice that expressed hepatitis B Ags in many tissues supports this interpretation, because the introduction of Ag-specific CTL into these mice resulted in immunopathology only in the liver (22) . The liver may be unique in its capacity to allow such interactions, because both Kupffer cells and sinusoidal endothelial cells express a high resting level of ICAM-1 (5, 6). In our mice, the systemic vasculature was not inflamed, and based on this argument plus the kidney data, we would argue that the lack of Ag presentation by non-bone marrow-derived cells in B63bm1 chimeras most likely did not affect the localization of OT-1 cells to organs other than the liver.
Increased apoptosis of activated CD8 ϩ T cells retained in livers with Ag presentation limited to bone marrow-derived cells
The percentage of TUNEL-positive OT-1 cells was consistently higher in the liver, compared with the spleen and kidney, in all three groups of chimeras (Fig. 4) . This percentage was similar to that observed in nonchimeric mice (7) (8) (9) (10) . The total number of TUNEL-positive OT-1 cells was, however, lower in B63bm1 chimeras (0.5 Ϯ 0.3 ϫ 10 6 ) compared with chimeras B63 B6 and bm13 B6.CD45. (1.2 Ϯ 0.49, 1.1 Ϯ 0.4 ϫ 10 6 ). This difference was because there were many fewer OT-1 cells in the livers of B63bm1 chimeras than B63 B6 or bm13 B6.CD45 (Fig. 3) . However, although there was significant variation in the percentage of TUNEL-positive OT-1 cells between experiments, the mean percentage of TUNEL-positive cells was elevated 1.6-fold (range, 1.1-2.0-fold) in the B63bm1 chimeras, relative to the B63 B6 chimeras. This increase was statistically significant (paired t test, n ϭ 4 experiments, p ϭ 0.04).
Immune mediated hepatic injury occurs in the absence of Ag presentation by hepatocytes
The B63bm1 chimeras allowed us to test the requirement for hepatocyte Ag presentation in the induction of hepatocyte injury by CD8 ϩ T cells. Serum aminotransaminases were elevated in all three groups of chimeras after peptide injection (Table I ). The aminotransaminase levels were at least 10 times greater than in the PBS injected controls, and this elevation was statistically significant by an unpaired t test ( p ϭ 0.001). The serum aminotransaminases in B63bm1 chimeras after peptide injection appeared to be twofold lower than in the B63 B6 and bm13 B6 chimeras, and despite the wide variation in individual values, this difference was statistically significant ( p ϭ 0.02). Injection of peptide into chimeras that had not received OT-1 cells did not result in significant elevation of aminotransaminases (AST 34 Ϯ 10.5 U/L, ALT 23 Ϯ 7.2 U/L). Fig. 5 shows liver histology in chimeras injected with PBS and SIINFEKL peptide. In all three groups of chimeras, there was a mononuclear infiltrate around the portal tract, around and central veins, and in liver lobules. This was associated with the eosinophilic bodies that are characteristic of hepatocyte apoptosis.
To determine whether the elevated aminotransaminase levels were associated with hepatocyte apoptosis, liver sections were stained using the TUNEL technique (Figs. 5 and 6 ). There were no TUNEL-positive nuclei in the livers of PBS-injected mice (Fig. 5,  b, f, and j) . However, TUNEL-positive nuclei were evident in the livers of all three groups of chimeras injected with peptide (Fig. 5,  d, h, and l) . The majority of TUNEL-positive nuclei were of small mononuclear cells, but TUNEL-positive hepatocyte nuclei were also present (Fig. 6, b, d, and f) . Identical TUNEL staining of kidney tissues from the same chimeras revealed few TUNEL-positive nuclei (Fig. 7, b, d, and f) . This is consistent with published data showing CD8 ϩ T cell apoptosis in the kidney (20) , but our quantitative analysis of OT-1 T cells shows that in absolute numbers very few OT-1 cells are undergoing apoptosis in this organ.
Discussion
The adhesion of activated T lymphocytes to vascular endothelium normally depends on selectin-addressin-mediated rolling, which slows the cells down, then firm adhesion based on the increased expression of endothelial adhesion molecules, which occurs as a result of local inflammation (1, 2) . However, this does not hold true for the liver, in which slow, intermittent blood flow through an anastomosing system of sinusoids is accompanied by the constitutive expression of adhesion molecules (5, 6, (25) (26) (27) . The normal liver retains activated T cells introduced via the portal vein, and this retention is mediated primarily by ICAM-1, which is present both on liver sinusoidal endothelium and on Kupffer cells (11) . Hepatic retention of activated T cells has a strong preference for CD8 ϩ T cells and is associated with apoptosis of a proportion of the retained cells. The liver has a large blood flow and occupies a unique position in the body, because all lymphocytes leaving both the spleen and the intestine pass through the liver before reaching the systemic circulation. This plus the unique vasculature of the liver raise the question whether intrahepatic T cell trapping and apoptosis have any implications for either gastrointestinal or systemic T cell responses.
It is not possible to test the effect of liver T cell retention on a systemic immune response by removing or bypassing the liver. We therefore chose to determine whether the capacity of the liver to present Ag regulates hepatic trapping and apoptosis of activated CD8 ϩ T cells. If such regulation were present, it would allow us a Injection of OT-1 T cells plus antigenic peptide resulted in liver damage in all groups of chimeras. In particular, there was damage in B63bm1 chimeras, in which the hepatocytes were unable to present Ag. Thus, the mechanism of damage was not dependent on specific CTL-mediated killing of the hepatocytes but was indirect. AST and ALT are in units per liter. to address whether there were any consequences for the behavior of T cells during a systemic CD8 ϩ T cell response. Our experimental approach to this issue was to construct three sets of radiation bone marrow chimeras, which allows us to determine whether the presentation of the SIINFEKL peptide on bone marrow-derived cells, non-bone marrow-derived cells or both contributes to intrahepatic trapping of CD8 ϩ T cells. The three main cellular components of the liver are the hepatocytes, the sinusoidal endothelial cells, and the bone marrow-derived Kupffer cells. In addition, there are bone marrow-derived intrahepatic lymphocytes, which are unlikely to play a key role in Ag presentation, and dendritic cells, which could play such a role. Previous studies have shown that isolated hepatocytes (28, 29) , sinusoidal endothelial cells (30, 31) , and Kupffer cells (31, 32) are all competent to present Ag in vitro. We therefore base our interpretation on the extrapolation that all of these cell types can present antigenic peptide in vivo.
The data in Fig. 3 show that Ag presentation by the non-bone marrow-derived cells of the liver is important in the trapping of CD8 ϩ T cells, whereas our previous studies implicate ICAM-1 and by implication its main ligand, LFA-1. In the intact liver, these two systems are likely to work together. It seems unlikely that the binding affinity of Ag-specific TCR-mediated recognition would contribute directly to adhesion between T cells and either endothelium or hepatocytes. Instead, such interactions would come into play after an activated T cell has formed an initial adhesion to endothelium or hepatocytes, most likely through a nonspecific adhesion molecule such as ICAM-1. The effect of TCR ligation on LFA-1/ICAM-1 interactions has been studied extensively in vitro. Stimulation of T cells by receptor cross-linking, or phorbol esters, increases both the level of LFA-1 expression and the affinity of LFA-1 for ICAM-1 (33, 34) . Thus, in activated CD8 ϩ T cells traversing liver sinusoids, Ag recognition would be expected to increase the avidity of LFA-1, promoting firm adhesion and the retention of the T cell in the liver.
The sinusoidal endothelium resembles inflamed vascular endothelium, because it constitutively expresses a high level of ICAM-1, but unlike inflamed vascular endothelium there is no expression of the B7-1 and B7-2 costimulatory molecules. This high level of expression of ICAM-1 on sinusoidal endothelium may contribute to the apoptosis of CD8 ϩ T cell seen in the liver. Stimulation of naive and memory CD8
ϩ , but not CD4 ϩ , T cells by anti-TCR Ab and ICAM-1 has been shown to result in both proliferation and apoptosis of the responding T cells (35) . This contrasts with anti-TCR and B7-1 stimulation, which results in a similar level of proliferation but reduced apoptosis. It is of interest that the costimulatory effect of ICAM-1 preferentially acts on CD8 ϩ T cells (35) (36) (37) . Thus, it is possible that ICAM-1 is the basis of both intrahepatic CD8 ϩ T cell retention and CD8 ϩ T cell apoptosis. However, other potential proapoptotic mechanisms are present in the liver. Our data suggest that bone marrow-derived Kupffer cells may be important in the induction of apoptosis, and in addition to ICAM-1 these cells express several proapoptotic molecules, including membrane bound FasL and soluble TNF-␣, whereas sinusoidal endothelium expresses galectin-1 (38 -41) . Furthermore, systemic T cell activation promotes FasL expression in several tissues, including liver (4). The contribution of these various cell types and proapoptotic molecules is not yet defined.
Massive liver retention and apoptosis of activated CD8 ϩ T cells is accompanied by pathology in the liver. In the original study of Huang et al. (7), we observed histological evidence of liver damage, and this was subsequently confirmed in another experimental model by elevation in serum aminotransaminases (9) . In these experiments, CD8 ϩ T cell activation was induced by the injection of antigenic peptide in TCR-transgenic mice, and such peptides may have been presented by hepatocytes so that hepatocytes would be targets for the cytotoxic effector function of CD8 ϩ T cells trapped in the liver. Hepatocyte injury by CD8 ϩ T cells after MHC-restricted recognition of hepatocyte Ags occurs, and it requires both perforin and CD95L cytotoxic mechanisms (23) . Because activated CD8 ϩ T cells express FasL and because hepatocytes can be killed by Fas ligation (24) , it has been hypothesized that T cell activation can result in hepatocyte injury in the absence of hepatocyte Ag presentation, a mechanism termed collateral damage (18) . In the present study, the hepatitis induced by systemic CD8 ϩ T cell activation when hepatocytes are unable to present the SIINFEKL peptide proves that activation of a small percentage of T cells can result in such "collateral" liver injury. The relative contributions of direct and collateral damage are very difficult to determine from these limited data. The fact that the mean serum ALT was ϳ2-fold lower in the B63bm1 chimeras could be taken to imply that about one-half of the liver damage was direct, whereas one-half was collateral. However, individual variation between experimental mice makes this difference hard to evaluate. Even if the difference proves to be real in a more extensive series of experiments, it could simply be because the absolute number of OT-1 cells in the liver is less in these chimeras. Whatever the relative contributions of the two mechanism in intact mice, the present data provide clear evidence for a novel mechanism of collateral liver injury, which may be involved in some disease states.
